Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma

Observational - CRKL Expression at the Protein Level in Rhabdomyosarcoma Tumors by Tissue Microarray (TMA)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01496573

Enrollment

Registered

2011-12-21

Start date

2011-12-31

Completion date

2016-05-31

Last updated

2016-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar Childhood Rhabdomyosarcoma, Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma

Brief summary

This research trial studies biomarkers in tumor tissue samples from younger patients with rhabdomyosarcoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer

Detailed description

PRIMARY OBJECTIVES: I. To demonstrate CRKL expression at the protein level in rhabdomyosarcoma tumors by tissue microarray (TMA). OUTLINE: Archived tumor tissue samples are analyzed for CRKL expression.

Interventions

OTHERlaboratory biomarker analysis

Correlative studies

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma specimens from the Children Oncology Group (COG) tumor microarrays (TMAs)

Design outcomes

Primary

Measure	Time frame
CRKL expression at the protein level	1 month

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026